AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

14-Feb-2022 - AiCuris Anti-infective Cures AG (AiCuris) and Hybridize Therapeutics (Hybridize) announced that they have entered into a worldwide licensing agreement for Hybridize’s BK virus (BKV) program. The licensed program is based on a novel RNA-based therapeutic approach developed by Hybridize. Under the ...

Former Merck CEO appointed Chair of the AiCuris Supervisory Board

26-May-2021 - AiCuris Anti-infective Cures AG announced that the Supervisory Board appointed Dr. Stefan Oschmann as chairman. He succeeds Helmut Jeggle, Chief Executive Officer of Salvia GmbH, who stepped down as planned from his role as Interim-Chairman of the initial Supervisory Board of AiCuris AG. Helmut ...

AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus (HCMV) Prophylaxis

Trial shows a dose-dependent effect on the prevention of HCMV re-activation/re-infection and an excellent tolerability

16-Feb-2012 - AiCuris GmbH &Co KG announced positive results from its placebo-controlled and dose-ranging trial with Letermovir (AIC246). In addition to excellent efficacy Letermovir demonstrates superior tolerability and safety and thus defines a novel standard for the control of HCMV in transplant ...

AiCuris Receives Orphan Drug Designation for Letermovir (AIC246) from FDA

09-Jan-2012 - AiCuris announced that AIC246 (Letermovir), the Company’s inhibitor against the human cytomegalovirus HCMV, has been granted Orphan Drug Designation in the US for the prevention of HCMV viremia and disease in at risk populations. This decision was made on 12 December 2011 by the FDA Office of ...

AiCuris: No Resistant Herpes Simplex Virus (HSV) Observed in Phase II Trial with Herpes Drug AIC316

08-Sep-2011 - AiCuris announces that it will present the results of the resistance analysis from the recently completed phase II clinical trial with AIC316 at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in USA, Chicago. AIC316 is one of AiCuris lead compounds and was ...

AiCuris’ HCMV Drug Letermovir (AIC246) Receives Fast Track from FDA

31-Aug-2011 - AiCuris announced that the Food and Drug Administration (FDA) of the United States has granted Fast Track designation for one of the company’s lead drugs, AIC246 (INN: Letermovir), an inhibitor of the human cytomegalovirus (HCMV).Fast Track designation is an FDA status reserved for products that ...

AiCuris’ Novel HSV Compound AIC316 Shows Efficacy in Phase II

20-Jul-2011 - Phase II results for AiCuris' novel non-nucleosidic herpes simplex virus (HSV) inhibitor AIC316 reveal safety and efficacy in persons with genital herpes. The data were presented at the 19th ISSTDR Meeting (International Society for Sexually Transmitted Diseases Research) in Quebec, Canada, by ...

AiCuris Receives Orphan Drug Designation for its Phase II Drug AIC246 for the Prevention of HCMV Disease

26-Apr-2011 - Wuppertal , Germany, April 21, 2011 / B3C newswire / - AiCuris announced today that AIC246, the Company’s inhibitor against the human cytomegalovirus HCMV, currently undergoing phase IIb testing, has been granted Orphan Drug designation for the prevention of HCMV disease. This decision was made ...

Dr. Marie-Paule Richard to Join AiCuris as CMO

20-Jan-2011 - AiCuris announced that Dr. Marie-Paule Richard has assumed the responsibility of Chief Medical Officer at AiCuris, Germany. Dr. Richard has over 24 years of experience in the pharmaceutical industry in leading global clinical development projects, supervising clinical-regulatory strategies, ...

AiCuris Completes Phase II Genital Herpes Trial with AIC316 Ahead of Time

10-Dec-2010 - AiCuris announced that the last subject has completed their Phase-II trial "A double-blind randomized placebo controlled dose-finding trial to investigate different doses of a new antiviral drug in subjects with genital HSV Type 2 infection". The trial has been completed two months earlier than ...